Advances in Neurological Disease Animal Models
Speaker: Dr. Dong Han, Sr. Scientist, Neurological Disease Team Lead at Biocytogen Neurological disorders affect over 3 billion people globally, encompassing a wide range of conditions that impact the brain, spinal cord, and peripheral nerves. Key examples include Alzheimer’s disease, Parkinson’s disease, autism spectrum disorders, and amyotrophic lateral sclerosis. These disorders significantly impair cognitive, emotional, […]
Read more
Advancing IBD Treatment: Leveraging Innovative Models and Therapies for Enhanced Drug Development
Speaker: Dr. Luo (Jack) Jia, Sr. Scientist/Study Director, Team Lead for Disease Modeling at Biocytogen Inflammatory Bowel Disease (IBD) is a chronic autoimmune disorder in which the body’s immune system triggers inflammation in the gastrointestinal tract. Affecting nearly one in 100 people in the United States, IBD presents significant challenges for treatment development due to […]
Read more
Empowering Discovery and Development of Bispecific ADCs With a Common Light Chain Antibody Library and a Novel Linker/Payload
Speaker: W. Frank An, PhD. Sr. Director of Antibody Therapeutics, Biocytogen Institute for Therapeutic Innovations, Biocytogen Pharmaceuticals About the webinar: Bispecific ADCs are a growing trend in the ADC field, offering improved efficacy and safety for the treatment of heterogeneous solid tumors. Designing bsADCs requires careful selection of targets, and is not without challenges, including the […]
Read more
Translational Animal Models of Atopic Dermatitis (AD) for Preclinical Studies
Speaker: Luke Yu, MD, Ph.D. Global head of Preclinical Pharmacology, Biocytogen Boston Corp & Biocytogen Pharmaceuticals Atopic Dermatitis is a chronic inflammatory skin condition characterized by redness, cracking, and scaling, often leading to painful sores. While the precise cause of AD remains unclear, a dysfunctional epidermal barrier and dysregulated immune responses (including IL-4, IL-13, IL-25, […]
Read more
Preclinical Pharmacology Services to Support Evaluation of Novel Cell & Gene Therapies
Speaker: Leila Kokabee, Ph.D, Senior Scientist II & Study Director, Preclinical Pharmacology in Biocytogen Boston Cell and gene therapies aim to treat diseases through the restoration or alteration of certain sets of cells, or by using cells to carry a therapy through the body. While cell therapies typically use engineered CAR-T or CAR-NK cells to […]
Read more
Maximize Your Drug Design Possibilities with RenNano-derived Fully Human Nanobodies
Speaker: Yi (Benny) Yang, PhD. Chief Scientific Officer, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Compared to traditional antibodies, nanobodies are significantly smaller in size, which is advantageous for penetrating tumors and crossing the blood-brain barrier. The protruding CDR3 regions of nanobodies make them better at targeting hidden epitopes, and their simple structure makes them ideal for […]
Read moreWebinar Categories
- Humanized Animal Models
- Others
- Renbiologics
